![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1794012
¼¼°èÀÇ Æ÷ÀÎÆ® ¿Àºê Äɾî(POC) ¼Òº¯ °Ë»ç ¹× ¿ä³» ³²¿ë ¾à¹° °Ë»ç ½ÃÀå(2025³â)Point-of-Care (POC) Urinalysis and Urinalysis Drugs of Abuse Testing Market, 2025 |
' ¼¼°èÀÇ Æ÷ÀÎÆ® ¿Àºê Äɾî(POC) ¼Òº¯ °Ë»ç ¹× ¿ä³» ³²¿ë ¾à¹° °Ë»ç ½ÃÀå(2025³â)' Àº Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¼Òº¯ °Ë»ç ¹× ³²¿ë ¾à¹° °Ë»ç ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®Çß½À´Ï´Ù. ÇöÀç ½ÃÀå ¿ªÇÐ, ±â¼ú µ¿Çâ, ÇâÈÄ ¼ºÀå °¡´É¼ºÀ» Á¶»çÇÏ¿© 2029³â±îÁöÀÇ ¼öÀͰú ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù.
Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î °Ë»ç´Â º´¿ø, ÀÇ¿ø, ¼Ò¸Å Ŭ¸®´Ð, °¡Á¤, °£º´ ½Ã¼³, Á÷Àå, ±º»ç ½Ã¼³ µî Áß¾Ó ÁýÁßÇü °Ë»ç ½Ã¼³ ÀÌ¿ÜÀÇ È¯ÀÚ ±Ùó¿¡¼ ½Ç½ÃµÇ´Â Áø´Ü ÀýÂ÷¸¦ Æ÷ÇÔÇÕ´Ï´Ù. POC °Ë»ç´Â Á¾Á¾ ºñ°Ë»ç½Ç Á÷¿ø¿¡ ÀÇÇØ ¼öÇàµÇ¸ç, µö ½ºÆ½, ½ºÆ®¸³, ·¡ÅÍ·² Ç÷οì Ä«¼¼Æ® µîÀÇ ¼öµ¿ ±â¼ú°ú ¼ÒÇüÈ ¹× ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º °øÇÐÀÇ Áøº¸·Î °¡´ÉÇØÁø ÈÞ´ë¿ë, ÈÞ´ë¿ë, ÄÄÆÑÆ®ÇÑ Å¹»ó Àåºñ¸¦ ¸ðµÎ Ȱ¿ëÇÕ´Ï´Ù.
¼Òº¯°Ë»ç´Â POC ºÐ¾ß¿¡¼ Áß½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ´ë»çÀå¾Ö, ½ÅÀ庴, ¹æ±¤¾Ï, ¿ä·Î °¨¿°Áõ µîÀÇ °Ç° ½ºÅ©¸®´×, Áø´Ü, ¸ð´ÏÅ͸µ µîÀÇ ¿ëµµ·Î ½Ã±â ÀûÀýÇÑ ÀÓ»ó ÆÇ´ÜÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¼Òº¯ °Ë»ç´Â ³²¿ë ¾à¹° °Ë»ç¿¡µµ ³Î¸® »ç¿ëµÇ¸ç ¹ý ÁýÇà ±â°ü, Çü»ç »ç¹ý, Á÷Àå ¹× ¸ÅÀå ä³Î¿¡¼ ³ôÀº ¼ö¿ä°¡ ÀÖÀ¸¸ç POC ½ÃÀåÀÇ »ó´çÇÑ Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù. ä´¢°¡ ºñħ½ÀÀûÀ̶ó´Â °ÍÀº ºÐ»êÇü ¹× ÀÚü °Ë»ç ¿ëµµ¿¡ ´ëÇÑ Ã¤¿ë¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, µö½ºÆ½ ¼Òº¯ °Ë»ç´Â ¼¼°è¿¡¼ °¡Àå ÆÇ¸Å·®ÀÌ ¸¹Àº POC °Ë»ç°¡ µÇ¾ú½À´Ï´Ù.
ÀÌ º¸°í¼´Â ¼¼ °¡Áö ÁÖ¿ä ÀåÀ¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù.
½ÃÀå ±Ô¸ð¿Í ¿¹ÃøÀº 2024³â ±âÁØÀ¸·Î ÇöÀç ´Þ·¯·Î Ç¥½ÃµË´Ï´Ù. ºÐ¼®Àº ¾÷°è Àü¹®°¡¿ÍÀÇ ÀÎÅͺä, ±â¾÷ µ¥ÀÌÅÍ, Á¤ºÎ °£Ç๰, »ê¾÷ Á¤º¸, ºÐ¼®°¡ º¸°í¼ µî ±¤¹üÀ§ÇÑ 1Â÷ ¹× 2Â÷ Á¶»ç¿¡ ÀÇÇØ µÞ¹ÞħµË´Ï´Ù.
Kalorama Information's "Point-of-Care (POC) Urinalysis and Urinalysis Drugs of Abuse Testing Market, 2025" provides an in-depth analysis of the global market for point-of-care urinalysis and drugs of abuse testing. The report examines current market dynamics, technological trends, and future growth potential, with revenue forecasts through 2029.
Point-of-care testing encompasses diagnostic procedures performed near the patient, outside centralized laboratory settings, including hospitals, physician offices, retail clinics, homes, nursing facilities, workplaces, and military locations. POC testing is often conducted by non-laboratory personnel and leverages both manual technologies-such as dipsticks, strips, and lateral flow cassettes-and portable, handheld, and compact benchtop instruments enabled by advances in miniaturization and microfluidics.
Urine testing plays a central role in the POC segment, supporting timely clinical decision-making for applications including health screening, diagnosis, and monitoring of metabolic disorders, kidney disease, bladder cancer, urinary tract infections, and other conditions. Urinalysis is also widely used in drugs of abuse testing, which commands a substantial share of the POC market with high demand across law enforcement, criminal justice, workplace, and over-the-counter channels. The non-invasive nature of urine collection has contributed to its adoption for decentralized and self-testing applications, making dipstick urinalysis the highest-volume POC test worldwide.
The report is organized into three key chapters:
Market size and forecasts are expressed in current U.S. dollars, based on 2024 as the base year. The analysis is supported by extensive primary and secondary research, incorporating industry expert interviews, company data, government publications, trade sources, and analyst reports.